SFG Wealth Management LLC. Invests $298,000 in AstraZeneca PLC (NASDAQ:AZN)

SFG Wealth Management LLC. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 4,055 shares of the company's stock, valued at approximately $298,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Cibc World Markets Corp grew its holdings in AstraZeneca by 1.1% in the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock worth $845,000 after acquiring an additional 142 shares during the last quarter. CoreCap Advisors LLC grew its holdings in AstraZeneca by 31.8% in the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after acquiring an additional 155 shares during the last quarter. Spinnaker Investment Group LLC grew its holdings in AstraZeneca by 3.1% in the 1st quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company's stock worth $423,000 after acquiring an additional 174 shares during the last quarter. Tiller Private Wealth Inc. grew its holdings in AstraZeneca by 5.7% in the 4th quarter. Tiller Private Wealth Inc. now owns 3,350 shares of the company's stock worth $219,000 after acquiring an additional 181 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC grew its holdings in AstraZeneca by 0.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock worth $2,313,000 after acquiring an additional 189 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Down 0.3%

AstraZeneca stock traded down $0.22 during trading hours on Friday, reaching $69.85. The stock had a trading volume of 3,133,365 shares, compared to its average volume of 5,216,608. The company has a fifty day simple moving average of $70.59 and a 200-day simple moving average of $70.48. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The stock has a market cap of $216.63 billion, a PE ratio of 28.05, a PEG ratio of 1.28 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. During the same period last year, the company posted $2.06 EPS. The company's quarterly revenue was up 7.2% compared to the same quarter last year. Analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.